Movement Alert|Abivax S.A. After-Hours Rise 4.46% in After-Hours Trading, company rejects short report as inaccurate and misleading

Market Focus
Nov 21

On November 21, Abivax S.A. rose 4.46% in After-Hours Trading to $74.8/share, with turnover of $837,400.

The move followed the company’s response to a short report published on November 20, stating that the report contained inaccurate and misleading claims and reaffirming the integrity of its clinical development program and Phase 3 ABTECT trial results in ulcerative colitis.

Earlier in Regular Trading, the stock had fallen after Wedbush lowered its price target to $96 from $118 while maintaining a neutral rating. That context highlights how the company’s formal rebuttal appears to have eased some of the pressure tied to the short-seller attack. Abivax S.A.’s lead candidate, obefazimod, is in Phase 3 development for moderately to severely active ulcerative colitis and is also being developed for Crohn’s disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10